GRAIL is an American biotechnology company focused on developing early cancer screening tests for individuals without symptoms. It is a subsidiary of Illumina, Inc. and is known for its Galleri test, a multi-cancer early detection (MCED) test that can detect a signal shared by more than 50 cancer types and predict the tissue type or organ associated with the signal to help healthcare providers determine next steps.

GRAIL

GRAIL, LLC

Galleri Test

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. 

For more information, please visit grail.com.

Community Guidelines: https://bit.ly/3xigb24 

6 Dimensions Capital

Ally Bridge Group

Sequoia Capital China

Blue Pool Capital

Genuity Science

Hillhouse Capital Group

China Merchants Securities

Canada Pension Plan Investment Board

Huangpu River Capital

PSP Investments

Illumina

GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. 

This accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu

This week GRAILers gathered to celebrate the upcoming #LunarNewYear. Best wishes and good fortune to all in the Year of the Dragon! 
#DiversityAndInclusion  

From addressing health disparities to advancing the science of cancer genomics, multi-cancer early detection has implications for many aspects of #cancer screening and care. We’re exploring the impacts of this technology on our podcast, The Cancer SIGNAL.

Subscribe here for new monthly episodes: https://bit.ly/42x1y9v

We’re excited to announce the name change of BIG (Black & Brown Influencers at GRAIL) in time for #BlackHistoryMonth! Anwell Wilbekin and Rich S.T Gilliam, co-leaders of BIG, unveil the new identity and outline upcoming events. We've curated insightful panel discussions on influence and health equity, along with a creative virtual paint night. Stay tuned for a month filled with celebration and empowerment at GRAIL! #DiversityAndInclusion #GRAILproud 

Proactive tools, like multi-cancer early detection tests, are helping people take more control of their health – but there’s more work to be done to help #CloseTheCareGap.

Ahead of #WorldCancerDay, we’re revisiting our podcast interview with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, as he discusses how we can address barriers to equity in cancer screening. Hear more in this episode of #TheCancerSignal: https://bit.ly/49eqd5z 

Find us on all major podcast platforms:  
Apple: https://apple.co/3W0dso3  
Spotify: https://spoti.fi/3Kbe9Z8 
Google: https://bit.ly/3Fmp9j4 

GRAL

COM:GRAIL

GRAIL

Last Close

16.38

22/11 21:00

Market Cap

431.58M

Beta: -

Volume Today

526.34K

Avg: -

name

linkedin url

crunchbase url

revenue

Description

peer of

investor of

competitor of

Metrics